纳入国家免疫规划 国产九价HPV疫苗在多地接种占比持续走高

Core Insights - The inclusion of the HPV vaccine in the national immunization program starting November 10, 2025, aims to provide free vaccinations to girls born after November 10, 2011, who are at least 13 years old [1] Group 1: HPV Vaccine Market Dynamics - The launch of the domestic nine-valent HPV vaccine offers a comprehensive and accessible option for cervical cancer prevention among eligible women [2] - There has been a notable increase in both consultation and vaccination rates for the domestic nine-valent HPV vaccine across various provinces, indicating growing acceptance and demand [2][4] - The domestic nine-valent HPV vaccine is perceived to have comparable efficacy and safety to imported versions, supported by large-scale clinical trials [2][3] Group 2: Factors Influencing Vaccine Uptake - The affordability of the domestic nine-valent HPV vaccine has significantly influenced the willingness of individuals to choose it over more expensive alternatives [3] - Public trust in domestic vaccines is increasing due to their proven safety, effectiveness, and established technology, leading to a shift in preference towards domestic options [3][4] - Government initiatives, including the "Accelerating the Elimination of Cervical Cancer Action Plan (2023-2030)," are promoting HPV vaccination and providing practical support for eligible girls [3] Group 3: Future Outlook - With ongoing policy support and increasing public acceptance, the domestic nine-valent HPV vaccine is expected to see rising consultation and vaccination rates, enhancing its reputation [4] - The expansion of supply, coverage areas, and improvement of grassroots vaccination services will further enhance accessibility and affordability for eligible women [4]